Bayer Corporation

05/06/2026 | Press release | Distributed by Public on 05/06/2026 06:05

Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline

  • Perfuse Therapeutics' investigational lead program shows potential to become one of the first disease-modifying treatments for both Glaucoma and Diabetic Retinopathy (DR)

  • High unmet medical need of patients with Glaucoma affecting up to 80 million people2 and Diabetic Retinopathy affecting around 146 million3 worldwide

  • Acquisition complements Bayer's pharmaceutical pipeline and strategically fits with Bayer's footprint and expertise in ophthalmology

Berlin, Germany and San Francisco, California USA, May 6, 2026 - Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR).

This represents one of the first potential treatments for Glaucoma and DR being studied for its ability to improve the visual field for Glaucoma patients and to improve contrast sensitivity and reduce ischemia in DR patients.

We are excited by the work of the team at Perfuse Therapeutics and encouraged by the potential of PER-001," said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. "With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients.
Juergen Eckhardt, M.D.
,
Head of Business Development and Licensing at Bayer Pharmaceuticals
Bayer Corporation published this content on May 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 06, 2026 at 12:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]